Table 2—

Change in A1C from baseline to week 30 and incidence of hypoglycemia stratified by sulfonylurea management group (ITT)

Sulfonylurea management groupChange in A1C (%)
Incidence of hypoglycemia (%)
Placebo5 μg exenatide10 μg exenatidePlacebo5 μg exenatide10 μg exenatide
MAX+0.2 ± 0.1−0.7 ± 0.1; P < 0.0001*−0.9 ± 0.1; P < 0.0001*15%22%35%
MIN+0.3 ± 0.1−0.4 ± 0.1; P < 0.0001*−0.6 ± 0.1; P < 0.0001*10%16%21%
  • Data are means ± SE, unless otherwise noted.

  • *

    * A1C change comparison for exenatide treatment versus placebo.